Preview

Current Pediatrics

Advanced search

EFFICACY OF THE METHOTREXATE PULSE THERAPY AND CYCLOSPORINE IN SEVERE SYSTEMIC JUVENILE RHEUMATOID ARTHRITIS

Abstract

The article provides for the data on the efficacy and safety of the methotrexate pulse therapy in combination with cyclosporine per os in patients with severe systemic juvenile rheumatoid arthritis. It has been shown that the bolus dosing of methotrexate in combination with cyclosporine for 8 weeks with the subse quent decrease in methotrexate dose and its intramuscular medication had provided for the remission progress of the systemic manifestations, joint syndrome and normalization of the laboratory activity indices among 65% of patients, earlier not responding to the treatment in conventional doses of methotrexate and cyclosporine by the third month of the observation. Bolus dosing of methotrexate with orally introduced cyclosporine was well tolerated by the patients, whereas the side effects were marked among 17% of patients, although they proved to be light and did not require cessation of the treatment. Thus, methotrexate pulse therapy in combination with orally introduced cyclosporine might be perspective for the treatment of severe systemic juvenile rheumatoid arthritis.
Key words: children, juvenile rheumatoid arthritis, methotrexate pulse therapy, treatment.

About the Authors

E.I. Alexeeva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


S.I. Valieva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


D.V. Apaeva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


T.M. Bzarova
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


K.B. Isaeva
Scientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow
Russian Federation


References

1. Алексеева Е.И., Литвицкий П.Ф. Ревматоидный артрит. Этиология, патогенез. Клиника. Алгоритмы диагностики и лечения. М.: Веди. 2007. 359 с.

2. Алексеева Е.И., Шахбазян И.Е. Принципы патогенетической терапии тяжелых системных вариантов ювенильного ревматоидного артрита. Серия: Аутоиммунные болезни. М. 2002. № 5. С. 127.

3. Клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М. 2005. С. 25–71, 120–140.

4. Dayer J. Interleukin 1 or tumor necrosis factor-alpha: which is the real target in rheumatoid arthritis? J. Rheumatol. 2002; 65: 10–15.

5. Strand V., Kavanaugh A. The role of interleukin–1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxford). 2004; 43 (3): 10–16.

6. Matei I., Matei L. Cytokine patterns and pathogenicity in autoimmune diseases. Rom. J. Intern. Med. 2002; 40 (1,4): 27–41.

7. Walsmith J., Roubenoff R. Cachexia in rheumatoid arthritis. Int. J. Cardiol. 2002; 85 (1): 89–99.

8. Насонов Е.Л. Метотрексат. Перспективы применения в ревматологии. М.: Филоматис. 2005. С. 196.

9. Woo P., Southwood T., Prieur A. et al. Randomized, placebo-controlled, crossover trial of low dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthr. Rheum. 2000; 43 (8): 1849–1857.

10. Chikanza I. Juvenile rheumatoid arthritis: therapeutic perspectives. Paediatr. Drugs. 2002; 4 (5): 335–348.

11. Zak M., Pedersen F. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford). 2000; 39 (2): 198–204.

12. Haagsma C., van Riel P. Combination of second line antirheumatic drugs. Ann. Med. 1997; 29 (2): 169–173.

13. Насонов Е.Л. Лечение ревматоидного артрита: современное состояние проблемы. РМЖ (Ревматология). 2006; 14 (8): 573–577.

14. Никишина И.П., Родионовская С.Р. Метотрексат в терапии ювенильного артрита. Пособие для врачей. М. 2006.

15. Родионовская С.Р., Никишина И.П. «Эра метотрексата» в детской ревматологии. Вопр. совр. педиатр. 2000; 3: 55–59.

16. Алексеева Е.И. Валиева С.И., Апаева Д.В. Эффективность и безопасность комбинированной иммуносупрессивной терапии циклоспорином и метотрексатом у больных тяжелым ювенильным ревматоидным артритом. Вопр. совр. педиатр. 2006; 5 (2): 19–27.

17. Алексеева Е.И., Валиева С.И., Апаева Д.В. Эффективность различных режимов иммуносупрессивной терапии циклоспорином и метотрексатом у больных системным вариантом ювенильного ревматоидного артрита. Вопр. совр. педиатр. 2007; 6 (2): 29–34.

18. Blumenauer B., Cranney A., Clinch J. et al. Quality of life in patients with rheumatoid arthritis: which drugs might make a difference? Pharmacoeconomics. 2003; 21 (13): 927–940.

19. Chikanza I. Juvenile rheumatoid arthritis: therapeutic perspectives. Paediatr. Drugs. 2002; 4 (5): 335–348.

20. Tugwell P., Pincus T., Yocum D. et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid Arthritis. N. Eng. J. Rheumatol. 1995; 333 (3): 137–142.

21. Hetland M., Stengaard–Pedersen K., Junker P. et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator initiated, multicenter, randomized, double blind, parallel group, placebo controlled study. Arthritis Rheum. 2006; 54 (5): 1401–1409.

22. Marchesoni A., Battafarano N., Arreghini M. et al. Radiographic progression in early rheumatoid arthritis: a 12 month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford). 2003; 42 (12): 1545–1549.

23. Farooqui A., Ahmad S., Mansuri F. Efficacy of cyclosporin A in refractory rheumatoid arthritis. J. Coll. Physicians. Surg. Pak. 2004; 14 (3): 139–141.

24. Ferraccioli G., Gremese E., Tomietto P. et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatol. 2002; 41: 892–898.

25. Ravelli A., Martini A. Early predictors of outcome in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 2003; 21 (5): 89–93.

26. http://rheumatology.oxfordjournals.org/cgi/content/full/42/8/989 - FNC1#FNC1Giacomelli R., Cipriani P., Matucci Cerinic M. et al. Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNF-alpha production without decreasing TNF alpha mRNA levels. An in vivo and in vitro study. Clin. Exp. Rheumatol. 2002; 20 (3): 365–372.

27. Матвеева Н.В. Применение высоких доз метотрексата в комбинированной терапии системной формы ювенильного ревматоидного артрита. Автореф. дис…канд. мед. наук. Красноярск. 2007. 19 c.


Review

For citations:


Alexeeva E., Valieva S., Apaeva D., Bzarova T., Isaeva K. EFFICACY OF THE METHOTREXATE PULSE THERAPY AND CYCLOSPORINE IN SEVERE SYSTEMIC JUVENILE RHEUMATOID ARTHRITIS. Current Pediatrics. 2008;7(1):29-34.

Views: 1326


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)